Clinical Trials
11
Active:0
Completed:5
Trial Phases
3 Phases
Phase 1:1
Phase 2:4
Phase 3:6
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
Phase 3
6 (54.5%)Phase 2
4 (36.4%)Phase 1
1 (9.1%)Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
Phase 2
Recruiting
- Conditions
- Motion Sickness, SpaceMotion SicknessSea Sickness
- Interventions
- Drug: DPI-386 Nasal GelDrug: Placebo Nasal Gel
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Repurposed Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05886660
- Locations
- 🇺🇸
NASA Johnson Space Center Neuroscience Laboratory, Houston, Texas, United States
Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
Phase 2
Recruiting
- Conditions
- Motion Sickness, SpaceParabolic FlightMotion Simulation
- Interventions
- Drug: DPI-386 Nasal GelDrug: Other (e.g., promethazine, meclizine)
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Repurposed Therapeutics, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT05852730
- Locations
- 🇺🇸
NASA Johnson Space Center Neuroscience Laboratory, Houston, Texas, United States
Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion
Phase 3
Completed
- Conditions
- Motion Sickness
- Interventions
- Drug: DPI-386 Nasal GelDrug: Placebo
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2023-03-21
- Lead Sponsor
- Repurposed Therapeutics, Inc.
- Target Recruit Count
- 503
- Registration Number
- NCT05548270
- Locations
- 🇺🇸
Santa Monica Clinical Trials, Santa Monica, California, United States
Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion
Phase 3
Completed
- Conditions
- Motion Sickness
- Interventions
- Drug: DPI-386 Nasal GelDrug: Placebo
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2021-09-17
- Lead Sponsor
- Repurposed Therapeutics, Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT04947423
- Locations
- 🇺🇸
Santa Monica Clinical Trials, Santa Monica, California, United States
Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion Sickness
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Repurposed Therapeutics, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT04272255
- Locations
- 🇺🇸
NAMRU-D, Dayton, Ohio, United States
- Prev
- 1
- 2
- 3
- Next
News
No news found